Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes - Wikidata - wikimedia - TriplyDB

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

http://www.wikidata.org/entity/Q34902754

about

Systemic therapies for pancreatic cancer--the role of pharmacogenetics Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.Base sequence context effects on nucleotide excision repair.Variants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx.The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.DNA repair gene ERCC1 C118T polymorphism predicts sensitivity of recurrent esophageal cancer to radiochemotherapy in a Chinese population.Utilisation of nanoparticle technology in cancer chemoresistance.The medicinal fungus Antrodia cinnamomea regulates DNA repair and enhances the radiosensitivity of human esophageal cancer cells.XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.ERCC1: impact in multimodality treatment of upper gastrointestinal cancer.Gastric cancer pharmacogenetics: progress or old tripe?Translational genomics and head and neck cancer: toward precision medicine.Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?Predictive role of host constitutive variants in neoadjuvant therapy of esophageal cancer.Effects of Novel Dinuclear Cisplatinum(II) Complexes on the Electrical Properties of Human Molt-4 Leukemia Cells.Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.Interrogation of nucleotide excision repair capacity: impact on platinum-based cancer therapy.Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.Molecular docking and molecular dynamics study on the effect of ERCC1 deleterious polymorphisms in ERCC1-XPF heterodimer.Genetic prediction of long-term survival after neoadjuvant chemoradiation in locally advanced esophageal cancer.ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas

P2860

Q27021716-53E3F73B-87AA-42DB-921B-DEEB26D330B7 Q28068930-D38B7C98-2BB8-4296-96FF-5CB6769A9E75 Q33406047-5A4B28FD-5891-486B-AA95-E2A65E64FA8F Q33903445-4E9BB077-BD66-4EEA-B517-5A57255708A8 Q33985880-92306D4A-67D7-4EAF-90FF-8517DA774B6E Q34143686-0D318781-9838-4FC7-A56F-E0A40C394468 Q34555379-05EA7098-48DE-4550-BE18-538EE1B0DC64 Q34676948-7A557463-2A68-4CE4-9B04-246B8E7E7136 Q34745772-3B35150C-3A54-49C4-99D0-4D1CF30E6761 Q35194655-D53F386D-27F7-4B89-9535-A3440035C6F4 Q35218636-FD255901-2391-4F90-AFE6-1108BDE54C85 Q35535744-C3D462F1-6131-4BF3-B00C-E6E7E2BB2453 Q35741165-26635F22-C70E-4F75-9DB9-A91B0E7F6A43 Q36247880-A482742E-26EA-4579-A0C3-5AFF6EE6C45A Q36421258-D265BF85-E32C-48C7-BA84-7D75ECC056D2 Q37395612-DDE3AB31-17D4-4CE9-99B5-9F0D0EEE851C Q37725406-C4CB2527-E0F9-47C1-B89A-6328DB0EF1FE Q37818224-37CB9262-1685-4343-9AF1-95980F615AC4 Q38120288-0BE45C22-1578-46D6-BDFA-5D3EB6BAAE45 Q38241804-7181CF20-6F6F-4358-8FE5-19A75B496B63 Q38276429-50592760-9840-408A-9980-64BE9F771068 Q38834922-39A9829A-1366-40DF-B466-9E956A3B3277 Q38940243-3B517DFE-AE40-43AE-ADC4-51C1538BAEFC Q41187621-A4FDE668-0D9C-44E2-8054-04F9A6841898 Q41701820-5A3A1A1F-69D0-4630-A922-8A7563401900 Q42566962-A8C1A0E5-9485-4DB5-A5B6-AECC37B44D4E Q42727098-8D1ED65C-2003-4E42-BC4F-5D89DBEF5AB5 Q42749109-1D657352-F275-4AC5-9026-C261F935868E Q43550190-C707EFDC-E0F8-4B26-B0D2-4C2069FC34FC Q44971469-3FC0F40E-195B-4E33-A73E-92E395F0583D Q52882648-C5278693-C65C-4246-9317-4E8E134EF73C Q53627469-692B7367-C2B7-47A4-B81C-C9E898B1B058 Q55455554-187B2DE7-09E0-42D0-BFB0-4450A8025C15 Q58763391-3B33FD73-24F0-4838-90B0-28551D28C6A1

P2860

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

http://www.wikidata.org/entity/Q34902754

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

@ast

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

@en

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

@nl

type

label

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

@ast

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

@en

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

@nl

prefLabel

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

@ast

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

@en

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

@nl

P1433

Q34902754-4048FDDD-72A5-4310-9198-20297628ACAE

P1476

Q34902754-30380B45-50A0-42D0-9581-06D93762B096

P2093

Q34902754-058B0FE3-965D-4665-BAD4-7B3C5B5F6F07

Q34902754-30414B6A-73BD-4ECD-8F5B-CB39577AA64D

Q34902754-35EB9A52-6716-478A-B743-57986188E10F

Q34902754-391E2CD7-78CC-4816-AB8A-7B3025A76E35

Q34902754-3A09127F-B164-4707-97FF-66EE237674B0

Q34902754-56DEA218-B6F3-4A95-B84D-97058F3B093C

Q34902754-5C443437-F13F-42E9-AFB0-8C106E83461D

Q34902754-895E1E7B-7CD3-4C8E-BAD3-025DD5ACE9C7

Q34902754-A1604966-4142-4574-BA97-BDFDCD32E7D4

Q34902754-BA3187D9-095E-4CEF-B80F-9D5CB110C44F

P2860

Q34902754-040FF6F4-9BAC-428C-8B8E-010ADC7E6D69

Q34902754-1610BD38-4B04-42E1-9796-2E1F3BCE0345

Q34902754-1D1B1798-C8EE-4405-9C4B-9B81353CA920

Q34902754-22640D95-46B7-4F2E-ACE9-97D6CB0D66C1

Q34902754-25730159-62AB-4708-BD92-E7E83F686A89

Q34902754-318F5391-F653-4257-8223-9BFCCCA242CB

Q34902754-442021CB-1FB1-4B50-9C7A-CF1079333C88

Q34902754-44D47AF4-F311-4F83-B533-B027F2089279

Q34902754-4CF9944B-6655-4181-99B9-1D1E80A13FDD

Q34902754-779B6195-CE6B-4484-A98B-5BAD83E2EA18

P304

Q34902754-A09ABB4C-C157-4943-8659-6934BA5319F5

P31

Q34902754-4AC03A60-B410-4DCD-B145-AD69925743EF

P356

Q34902754-409286E3-9857-4198-8A68-CEA829767555

P433

Q34902754-12ADAA47-1485-4C16-B2A9-63A23A9A51A0

P478

Q34902754-98CE3A82-922F-46D4-A795-D235BCD77264

P50

Q34902754-D93D623F-FF30-4741-BF38-7DAB8322603E

P577

Q34902754-925AC539-C441-4CDD-ACF3-C925018F2205

P698

Q34902754-7847ECC0-57F0-4C72-AF94-1CD2963FE5E7

P932

Q34902754-4505DC08-4D4A-4948-95E5-A1FEDC08D49D

P356

FPC.0B013E32832F3010

P1433

Pharmacogenetics and Genomics

P1476

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

@en

P2093

Ariela L Marshall

http://www.w3.org/2001/XMLSchema#string

Clement Ma

http://www.w3.org/2001/XMLSchema#string

David C Christiani

http://www.w3.org/2001/XMLSchema#string

Frances A Shepherd

http://www.w3.org/2001/XMLSchema#string

John C Wain

http://www.w3.org/2001/XMLSchema#string

Kofi Asomaning

http://www.w3.org/2001/XMLSchema#string

Li Su

http://www.w3.org/2001/XMLSchema#string

Matthew H Kulke

http://www.w3.org/2001/XMLSchema#string

Penelope A Bradbury

http://www.w3.org/2001/XMLSchema#string

Rebecca S Heist

http://www.w3.org/2001/XMLSchema#string

P2860

A New Statistical Method for Haplotype Reconstruction from Population Data

Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells

Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.

Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk.

Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis.

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.

Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel.

P304

613-625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0B013E32832F3010

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19620936

http://www.w3.org/2001/XMLSchema#string

P932

3085844

http://www.w3.org/2001/XMLSchema#string